Radicava trials

[Anne827]

My Neurologist said that in a clinical trial in Europe Radicava is not making a difference in ALFSR-R scores.
I was wondering if anyone else’s Dr told them about this trial?

 

[Nikki J]

That was the ADORE trial which did indeed fail. It technically wasn’t radicava but a slightly different formulation. Radicava ors is 105 mg dose this was 100 mg. It also had a slightly different formulation. One was granules. The other an oral suspension. MT pharma claims this makes a difference in bioavailability.

Ferrer reports top-line results from Phase III ADORE study in ALS | Ferrer

Ferrer reports that Phase III ADORE (EudraCT 2020-003376-40 / NCT05178810) clinical trial of oral edaravone formulation (FAB122) in amyotrophic lateral sclerosis (ALS) patients did not meet primary or key secondary endpoints.

www.ferrer.com

Press Releases - Mitsubishi Tanabe Pharma America

See how we're shaping the future of healthcare on Mitsubishi Tanabe Pharma America's press releases page.

www.mt-pharma-america.com

 

[Anne827]

Thanks for link. I think this will be my last round of Radicava.